Table 1

Results of economic (cost) studies

Country

UK [11]

US [12]

US [12]

Canadian [14]

Canadian [13]

French [4]

French [4]


Cost year

? (1996–1997)

? (1994–1996) 1995*

? (1994–1996) 1995*

1997

1999

1996

1996

Patient group

UK only (n = 191)

US only (n = 936)

All ESSENCE patients

Canadian only

Canadian

French only

All ESSENCE

(n = 1259)

hypothetical cohort

(n = 133)

patients

Cost-effectiveness

30 days

30 days

30 days

1 year

30 days

30 days

30 days

assessed at

Currency

£UK

$US

$US

$CAN

$CAN

FF

FF

Cost savings

Base case 1

23.68

763

661

1485

44

9993

1555

Base case 2

na

1172

688

na

na

2804

1014

Sensitivity analysis best case

Not available for cost differences

Net costs in only 14%**and 6%*** of 200

Not available

3167

435

12019

1876

Sensitivity analysis worst

bootstrap samples

-174

-299

1518

542

case

In £UK (in cost year as above)

Base case 1

23.68

499

432

812

25

980

152

Base case 2

na

766

450

na

na

275

99

Sensitivity analysis best case

Not available for cost differences

Net costs in only 14%** and 6%*** of 200

Not available

1733

247

1178

184

Sensitivity analysis worst

bootstrap samples

-95. Net costs in only

-170

149

53

case

3% of 1000 bootstrap

samples


Notes ? means unclear na = not applicable Negative cost savings indicates a net cost * taken as 1995 for currency conversion ** initial hospitalisation *** cumulative total Cost savings converted to UK pounds using Purchasing Power Parities (PPP) [23] (this eliminates the differences in price levels between countries). ESSENCE patients were the patients in the 'Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events' trial [6]

Nicholson et al. BMC Cardiovascular Disorders 2001 1:2   doi:10.1186/1471-2261-1-2

Open Data